# EDGAR Filing Document

**Accession Number:** 0001659617
**File Stem:** 0000000000-25-006124
**Filing Date:** 2025-6
**Character Count:** 4066
**Document Hash:** 7ea8100d9dca5a292943783b420ed319
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-25-006124.hdr.sgml**: 20250829

**ACCESSION NUMBER**: 0000000000-25-006124

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250610

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Moleculin Biotech, Inc.
- **CENTRAL INDEX KEY:** 0001659617
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 474671997
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 377-08038

**BUSINESS ADDRESS:**
- **STREET 1:** 5300 MEMORIAL DRIVE
- **STREET 2:** SUITE 950
- **CITY:** HOUSTON
- **STATE:** TX
- **ZIP:** 77007
- **BUSINESS PHONE:** 713-300-5160

**MAIL ADDRESS:**
- **STREET 1:** 5300 MEMORIAL DRIVE
- **STREET 2:** SUITE 950
- **CITY:** HOUSTON
- **STATE:** TX
- **ZIP:** 77007
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001437749-25-018355

## Text-Extract

```

                                                               June 10, 2025

Walter V. Klemp
President, Chief Executive Officer and Chairman
Moleculin Biotech, Inc.
5300 Memorial Drive, Suite 950
Houston, TX 77007

        Re: Moleculin Biotech, Inc.
            Amendment No. 1 to Registration Statement on Form S-1
            Filed June 6, 2025
            File No. 333-287727
Dear Walter V. Klemp:

     We have reviewed your amended registration statement and have the
following
comments.

        Please respond to this letter by amending your registration statement
and providing
the requested information. If you do not believe a comment applies to your
facts and
circumstances or do not believe an amendment is appropriate, please tell us why
in your
response.

       After reviewing any amendment to your registration statement and the
information
you provide in response to this letter, we may have additional comments.

Amendment No. 1 to Registration Statement on Form S-1
Risk Factors
Risks Related to this Offering
Your ownership may be diluted if additional capital stock is issued to raise
capital . . . , page
7

1.     We note your disclosure on page 6 that you will require additional
capital funding and
       on page 8 that you believe the net proceeds from this offering will
satisfy your capital
       needs into the third or fourth quarter of 2025. Please revise to add
risk
       factor disclosure regarding the risk that future issuances of your
capital stock in the
       near term may result in triggering the reset provision in your Series E
Warrants and
       increase the number of shares of common stock underlying each warrant.
 June 10, 2025
Page 2
Description of Common Warrants
Series E Warrant
Duration and Exercise Price, page 17

2.     We note your disclosure on page 17 that a future offering conducted at a
purchase
       price per share less than the exercise price of the Series E warrants
would result in an
       adjustment to the number of shares underlying each Series E warrant.
Please revise
       this section to explain the reset provisions by providing examples
illustrating the
       impact to the number of shares underlying the warrants under various
pricing
       scenarios. Revise here and on the coverpage to highlight the maximum
number of
       shares issuable upon exercise of the warrants assuming a reset at the
floor price. Also,
       revise your Risk Factor section to reflect the risks of dilution and, to
the extent not
       prohibited, short-selling activity by Series E warrant holders.

       Please contact Daniel Crawford at 202-551-7767 or Joe McCann at
202-551-6262
with any other questions.

                                                            Sincerely,

                                                            Division of
Corporation Finance
                                                            Office of Life
Sciences
cc:   Cavas Pavri, Esq.

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._